Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort
The Journal of Clinical Endocrinology & Metabolism · 19.05.2026 · 111 (6) · 1713-1726
DOI: 10.1210/clinem/dgaf665 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 12.12.2025. Verfasst von Ria Talathi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Metabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Intra-Abdominal Fat, Estradiol, Liver, Gender-Affirming Procedures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH/NHLBI, Robert Wood Johnson Foundation.
Abstract (Originalsprache)
Context
Data on the metabolic effects of contemporaneous gender-affirming hormone therapy (GAHT) are limited.
Objective
To characterize the metabolic effects of GAHT ie, estradiol with anti-androgen therapy.
Design
Prospective observational study with a 12-month follow-up period.
Setting
Academic medical center in greater Boston, Massachusetts, USA.
Participants
Twenty-six transgender women and nonbinary individuals with no history of cardiovascular disease or diabetes who were either planning to initiate or who had recently initiated GAHT consisting of 17 beta(β)-estradiol and anti-androgen therapy. Intervention(s) GAHT. Main Outcome Measure(s) The prespecified primary outcome was the change in visceral adipose tissue (VAT). Prespecified secondary outcomes included change in bone density, insulin sensitivity, and intrahepatic triglyceride content (hTG).
Results
Median age of participants was 26 (20, 30) years. After 12 months, VAT mass and volume did not change. While lumbar, total hip, and femoral bone density increased, insulin sensitivity did not change. hTG decreased over 12 months (median change: −0.2 [−1.3, 0.1]%, P = .03). Total lean body mass and the appendicular lean body mass/height2 decreased (mean change: −0.31 ± 0.38 kg/m2, P = .0003). Systemic triglycerides levels increased, whereas high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, did not change over 12 months. Free testosterone levels at follow-up independently predicted the change in hTG, controlling for estradiol levels, body mass index, and waist-to-hip ratio at follow-up.
Conclusion
Key indices of metabolic health, such as VAT and insulin sensitivity, did not change after 12 months of GAHT. Appendicular lean body mass/height2, a predictor of sarcopenia, unfavorably decreased, while hTG favorably decreased. Awareness of the metabolic effects of GAHT may lead to the implementation of strategies aimed at mitigating sarcopenia risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- Heart and Vascular Center, Semmelweis University, Budapest 1122, Hungary.
- Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
- Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- Division of Healthcare in Adult Populations, Duke University School of Nursing, Durham, NC 27710, USA.
ORCID-Profile: Hang Lee, Mabel Toribio
Förderung
- NIH/NHLBI
- Robert Wood Johnson Foundation
Zitieren
APA
Talathi, R., Juhasz, V., Delgado, M., Quinaglia, T., Ghamari, A., Wang, M., Alhallak, I., Stinebaugh, S., Campbell, S., Stockman, S. L., Ozturk, M. A., Ahmadi, S. M., Looby, S. E., Lee, H., Poteat, T. C., Szczepaniak, L. S., Zanni, M. V., Neilan, T. G., & Toribio, M. (2026). Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort. The Journal of Clinical Endocrinology & Metabolism, 111(6), 1713-1726. https://doi.org/10.1210/clinem/dgaf665
Vancouver
Talathi R, Juhasz V, Delgado M, Quinaglia T, Ghamari A, Wang M, et al. Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort. The Journal of Clinical Endocrinology & Metabolism. 2026;111(6):1713-1726. doi:10.1210/clinem/dgaf665
BibTeX
@article{Talathi2026,
author = {Talathi, Ria and Juhasz, Vencel and Delgado, Matilda and Quinaglia, Thiago and Ghamari, Azin and Wang, Melissa and Alhallak, Iad and Stinebaugh, Sarah and Campbell, Sophia and Stockman, Sara L and Ozturk, Mustafa A and Ahmadi, Sadia M and Looby, Sara E and Lee, Hang and Poteat, Tonia C and Szczepaniak, Lidia S and Zanni, Markella V and Neilan, Tomas G and Toribio, Mabel},
title = {Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {6},
pages = {1713--1726},
doi = {10.1210/clinem/dgaf665}
}
EUVIMED